A novel monoclonal antibody against a synthetic peptide from ?-actin can react with its corresponding protein
Date
2015Author
Amini, N
Bayat, A-A
Zarei, O
Hadavi, R
Mahmoudian, J
Mahmoudi, AR
Darzi, M
Rabbani, H
Jeddi-Tehrani, M
Metadata
Show full item recordAbstract
Actin is one of the most widely studied structural and multifunctional housekeeping proteins in eukaryotic cells with important roles in many cell functions. Antibodies against ?-actin and other housekeeping gene-encoded proteins are used as internal loading controls in Western blot analyses. The aim of this study was to produce a monoclonal antibody (mAb) against a synthetic peptide derived from N-terminal region of ?-actin and to study its reactivity with different organisms. A synthetic peptide, derived from ?-actin, was designed and used to produce a mAb by hybridoma technology. The produced antibody (clone 4E5- A10) was purified by an affinity chromatography column followed by characterization of purified mAb using SDS-PAGE, ELISA and Western blot. Our results showed that 4E5-A10 was an IgM and had desired purity and excellent reactivity with the immunizing peptide with an affinity constant of 2.7أ—108 M-1. It could detect a band of about 45 kDa, corresponding to ?-actin, in Western blot. Furthermore, it could react in a more sensitive manner and with a wider range of organisms than a known commercial anti ?-actin antibody. Our data suggest that 4E5-A10 can act as a sensitive probe for detection of ?-actin as an internal loading control, for a wide range of organisms, in Western blot analyses. é 2015 Bentham Science Publishers.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Target therapy of cancer: Implementation of monoclonal antibodies and nanobodies
Majidi, J; Barar, J; Baradaran, B; Abdolalizadeh, J; Omidi, Y (2009)In the past decades, the mainstay of systemic therapy for solid and haematological malignancies was chemotherapy; nevertheless this modality has the drawbacks such as drug resistance and eliciting sever cytotoxicity in the ... -
Antibody humanization methods for development of therapeutic applications
Ahmadzadeh, V; Farajnia, S; Feizi, MAH; Nejad, RAK (2014)Recombinant antibody technologies are rapidly becoming available and showing considerable clinical success. However, the immunogenicity of murine-derived monoclonal antibodies is restrictive in cancer immunotherapy. Humanized ... -
Isolation and characterization of anti ROR1 single chain fragment variable antibodies using phage display technique
Aghebati-Maleki, L; Younesi, V; Jadidi-Niaragh, F; Baradaran, B; Majidi, J; Yousefi, M (2017)Receptor tyrosine kinase-like orphan receptor (ROR1) belongs to one of the families of receptor tyrosine kinases (RTKs). RTKs are involved in the various physiologic cellular functions including proliferation, migration, ...